Home › Forums › Main Forum › Experts Corner › Harvoni vs Daklinza

Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • 21 February 2017 at 3:18 am #25367
    dope-on-a-rope.jpgDr James
    • Guardian Angel
    • ★★★★★
    @fixhepc

    Recently we saw SVR rates of 91-92% reported for Harvoni in a big (4200+) group of patients treated by the US VA.

    http://fixhepc.com/forum/experts-corner/1316-harvoni-delivers-only-91-92-svr12-in-va-study-n-4365.html

    At CROI 2017 further results from the German GECCO study were reported, and if you have a look at figure 3 there is a strong suggestion that Sofosbuvir + Daclatasvir is a better choice for GT1 than Harvoni. We have seen similar results with generics.

    http://www.croiconference.org/sites/default/files/posters-2016/584.pdf

    GECCO.pdf

    YMMV

    3 March 2017 at 12:29 pm #25489
    Avatar photoLondonGirl
    • Guardian Angel
    • ★★★★★
    @londongirl

    I support this by my own experience as a previous GT1a that extended with Sofosbuvir/Daclatasvir . :+1:

    GT1a Dec14 F2/8.7 VL 900000-2.5M
    Jan16 Hepcivir-L MonkMed/Redemption
    Baseline: VL 913575 Alt 76 Platelets low
    Wk2 VL1157 Alt 23
    DET Wk 8 VL 32 Alt19 ‘In the slow lane’
    June16 Fibro 5.7 F0/1 LIF 1.5
    Wk 11 VL<12 Alt 13 Det/Unq
    Extending tx 12 wks Mylan Sofo/Dac MonkMed
    Wk 14 VL <12 Det/Unq
    Wk 16 VL UNDETECTED
    Wk 22 + 4 Wks Sunprevir FixHepC
    Wk 24 UNDETECTED Alt 13
    Wk 12 post tx SVR12 Wk 26 SVR24
    Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC

  • Author
    Posts
Viewing 2 posts - 1 through 2 (of 2 total)
  • You must be logged in to reply to this topic.